title: [Analysis of the components of porcine liver hydrolysate and examination of the antioxidant activity and angiotensin converting enzyme (ACE)-inhibiting activity].
abstract: Hypertension and oxidant stress predispose to the onset and progression of arteriosclerotic diseases. In this study, the components of two kinds of porcine liver hydrolysates (LH-I and LH-II) were analyzed, and the antioxidant effects and angiotensin converting enzyme (ACE)-inhibiting effects of LH-I and LH-II were examined in vitro. Furthermore, the effects of LH-I and LH-II on the blood pressure were examined in spontaneously hypertensive rats (SHR). The results showed that peptides and amino acids accounted for 70% or more of the constituents of both LH-I and LH-II. The results of gel filtration HPLC showed that most of the nitrogen-containing components were peptides or amino acids with molecular weights of 6000 or less. The DPPH radical scavenging activities of LH-I and LH-II were 55.6 and 38.1 μM Trolox Equivalent/g, respectively. The IC(50) values for the ACE-inhibiting activity of LH-I and LH-II were 0.18 and 0.31 mg/mL, respectively. Oral administration of 1 g/rat of LH-I or LH-II to SHR resulted in significant lowering of the blood pressure. These findings indicate that both LH-I and LH-II have antioxidant activity and ACE-inhibiting activity. Moreover, both exerted a blood pressure-lowering effect in SHR. The antioxidant activity and ACE-inhibiting activity of LH-I and LH-II are presumed to be based on the actions of the component peptides.
authors.affiliation: Interdisciplinary Graduate School of Agriculture and Engineering, University of Miyazaki, Japan.
authors.forename: Naonori
authors.initials: N
authors.lastname: Inoue
authors.forename: Atsuko
authors.initials: A
authors.lastname: Hamasaki
authors.forename: Shuji
authors.initials: S
authors.lastname: Hidaka
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Miura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Fukahori
authors.forename: Masugi
authors.initials: M
authors.lastname: Maruyama
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kawahara
authors.forename: Kazuyoshi
authors.initials: K
authors.lastname: Ohta
authors.forename: Michio
authors.initials: M
authors.lastname: Muguruma
mesh_terms: D000284:Administration, Oral; D000806:Angiotensin-Converting Enzyme Inhibitors; D000818:Animals; D000959:Antihypertensive Agents; D000975:Antioxidants; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D016166:Free Radical Scavengers; D066298:In Vitro Techniques; D008099:Liver / Q000378:metabolism*; D008297:Male; D010455:Peptides / Q000302:isolation & purification / Q000494:pharmacology; D011492:Protein Hydrolysates / Q000008:administration & dosage / Q000032:analysis* / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D011918:Rats, Inbred SHR; D013552:Swine
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000975:Antioxidants; D016166:Free Radical Scavengers; D010455:Peptides; D011492:Protein Hydrolysates